Actinogen Medical receives $9 million R&D tax rebate for 2024.
Posted on: 11/11/2024
Actinogen's Xanamem shows significant benefits for depression in phase 2a trial.
Posted on: 11/08/2024
Actinogen Medical releases promising trial results and financial updates.
Posted on: 21/07/2024